Related Experiment Video
Updated: May 23, 2026
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
High-throughput screening for novel drug combinations using patient-derived organoids
Natalie Thielen1, Chaoyuan Kuang2, Edward Chu2
1Montefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.
Patient-Derived Organoids (PDO) offer advanced 3D tissue models for high-throughput screening (HTS). Technological advancements in PDO-based HTS enhance combination therapy discovery for precision medicine.
Area of Science:
- Biotechnology
- Cancer Research
- Drug Discovery
Background:
- Patient-Derived Organoids (PDO) represent 3D culture systems that more accurately mimic human tissues than 2D cell lines.
- PDOs preserve patient-specific traits, cellular diversity, and spatial layout, making them crucial for high-throughput screening (HTS).
- Tumor heterogeneity and therapy resistance necessitate combination screening, with recent advancements enabling larger-scale studies.
Purpose of the Study:
- To review technological strategies for adapting PDOs to screening platforms.
- To discuss design considerations for combination screening using PDOs.
- To explore analytical methodologies, readout technologies, challenges, and future developments in PDO-based HTS.
Main Methods:
- Standardized matrices, smaller plate formats, and automation improve uniformity and workflow efficiency in PDO screening.
- Microfluidic systems offer precise concentration gradients and sequential treatment delivery for complex combination designs.
- Advanced assay readouts beyond viability, including label-free imaging and quantitative morphology, provide sensitive response measures.
Main Results:
- PDO-based HTS is a powerful approach for identifying and refining therapeutic combinations.
- Diverse analytics, including dose-response metrics and synergy calculations, are essential for understanding complex combination responses.
- Technological progress in standardization, automation, microfluidic delivery, and integrated analysis is key.
Conclusions:
- Ongoing advancements in PDO-based HTS platforms promise to accelerate the discovery of effective combination treatments.
- Improved assay standardization, automation, microfluidic delivery, and integrated analysis will enhance the translation of findings into precision medicine.
- PDO-based HTS facilitates the identification and optimization of combination therapies for improved patient outcomes.
